Molecular and biological determinants of the cytotoxic actions of camptothecins: Perspective for the development of new topoisomerase I inhibitors

Annals of the New York Academy of Sciences

Volumn 922, Issue , 2000, Pages 11-26

  Kohn, K W ^a   Pommier, Y ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; CANCER; CANCER CHEMOTHERAPY; CONFERENCE PAPER; CYTOTOXICITY; DRUG DESIGN; DRUG MECHANISM; HUMAN; HUMAN CELL;

EID: 0034513226     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb07021.x     Document Type: Conference Paper

References (57)

1. Camptothecin
2. Camptothecin and taxol: Discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture
3. Camptothecin and taxol: Discovery to clinic
4. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca accuminata
5. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
6. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: Evidence for a specific receptor site and a relation to antitumor activity
7. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
8. Antineoplastic agents from plants
9. Homocamptothecins: Synthesis and antitumor activity of novel E-ring-modified camptothecin analogues
10. Homocamptothecin, an E-ring modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties
11. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks
12. Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I-DNA binary complex
13. Topoisomerase II inhibitors: The epipodophyllotoxins, m-AMSA, and the ellipticine derivatives
14. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
15. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives
16. Differential interactions of camptothecin lactone and carboxylate forms with human blood components
17. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2
18. The mechanim for the inhibition of acetylcholinesterases by irinotecan (CPT-11)
19. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line
20. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin
21. Camptothecin resistance: Role of the ATP binding cassette (ABC) half-transporter, mitoxantrone-resistance (MXR), and potential for glucuronidation in MXR-expressing cells
22. Camptothecins: Mechanism of action and resistance
23. 10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells
24. Novel 7-alkyl methylenedioxycamptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells
25. Novel A,B,E-ring-modified camptothecins displaying high lipophilicity and markedly improved human blood stabilities
26. Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110
27. Using yeast to understand drugs that target topoisomerases
28. Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison
29. Novel antitumor indolocarbazole compound 6-N-formylamino-12, 13-dihydro-1, 11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2, 3-a] pyrrolo[3,4-c] carbazole-5,7(6H)-dione (NB-506): Induction of Topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity
30. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents
31. Topoisomerase I inhibitors: Selectivity and cellular resistance
32. Inhibition of topoisomerase I function by nitidine and fagaronine
33. Human DNA topoisomerase I: Quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage
34. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute
35. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes
36. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin
37. SUMO-1 conjugation to topoisomerase 1: A possible repair response to topoisomerase-mediated DNA damage
38. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cells
39. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin
40. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells
41. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines
42. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: Evidence for cell cycle-independent toxicity
43. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates DNA-PK/RPA complexes
44. Interaction of DNA-dependent protein kinase with DNA and with Ku: Biochemical and atomic-force microscopy studies
45. Replication protein A: A heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism
46. Interaction between replication protein A and p53 is disrupted after UV damage in a DNA repair-dependent manner
47. Characterization of the p53 tumor suppressor pathway in cell lines of the NCI anticancer drug screen and relationships with chemosensitivity
48. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells
49. Quantitative structure activity relationships on 5-substituted terbenzimidazoles as topoisomerase I poisons and antitumor agents
50. Molecular interaction map of the mammalian cell cycle control and DNA repair systems
51. Chk2/hCds1 functions as a DNA damage checkpoint in G1 by stabilizing p53
52. DNA damage-induced activation of p53 by the checkpoint kinase Chk2
53. Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase
54. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
55. Fools rush in
56. 14-13-3σ is required to prevent mitotic catastrophe after DNA damage
57. p53 regulates a G2 checkpoint through cyclin B1